Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Tcr2 Therapeutics Inc (TCRR)

26.68   -0.32 (-1.19%) 02-25 12:10
Open: 27.69 Pre. Close: 27
High: 28.08 Low: 26.55
Volume: 114,113 Market Cap: 1,014M
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 27.77 - 27.925 27.925 - 28.067
Low: 26.047 - 26.247 26.247 - 26.43
Close: 26.709 - 27 27 - 27.266

Technical analysis

as of: 2021-02-25 11:51:34 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 33.13     One year: 36.10
Support: Support1: 24.25    Support2: 20.18
Resistance: Resistance1: 28.37    Resistance2: 30.91
Pivot: 28.09
Moving Average: MA(5): 27.42     MA(20): 27.64
MA(100): 26.70     MA(250): 18.89
MACD: MACD(12,26): -0.47     Signal(9): -0.38
Stochastic oscillator: %K(14,3): 20.82     %D(3): 33.65
RSI: RSI(14): 42.24
52-week: High: 35.86  Low: 5.84  Change(%): 124.7
Average Vol(K): 3-Month: 52586  10-Days: 30785

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
TCRR has closed above bottom band by 8.1%. Bollinger Bands are 47.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to TCRR's normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 19 Feb 2021
Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares? - Simply Wall St

Wed, 17 Feb 2021
TCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference - Yahoo Finance

Thu, 04 Feb 2021
TCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors - GlobeNewswire

Wed, 27 Jan 2021
Is Tcr2 Therapeutics Inc (TCRR) A Winner in the Healthcare Sector? - InvestorsObserver

Tue, 19 Jan 2021
Tcr2 Therapeutics Inc (TCRR) Stock Falls -0.03% This Week; Should You Buy? - InvestorsObserver

Fri, 08 Jan 2021
TCR2 Therapeutics provides 2021 data and regulatory milestones - Seeking Alpha

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 38
Shares Float (M) 20
% Held by Insiders 1.57
% Held by Institutions 96.72
Shares Short (K) 3,340
Shares Short P. Month (K) 2,460

Stock Financials

EPS -2.400
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 7.560
Profit Margin
Operating Margin
Return on Assets (ttm) -18.1
Return on Equity (ttm) -29.0
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.639
Qtrly Earnings Growth
Operating Cash Flow (M) -54
Levered Free Cash Flow (M) -35

Stock Valuations

PE Ratio -11.13
PEG Ratio
Price to Book value 3.53
Price to Sales
Price to Cash Flow -18.95

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.